CURRENT STATUS OF PERSONALISED PLATELET INHIBITOR TREATMENT IN CARDIOLOGY
- In: B2 - Reducing inter-individual variability: the power of a practitioner/scientist team approach on Thursday, 1 October 2015, 14:30-17:30
- At: Düsseldorf (Germany) (2015)
- Type: Presentation
- By: TRENK, Dietmar (Universitaets-Herzzentrum Freiburg-Bad Krozingen, Clinics for Cardiology and Angiology II, Clinical Pharmacology, Bad Krozingen, Germany)
- Co-author(s): Dietmar Trenk
Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is standard of care in patients undergoing percutaneous coronary intervention (PCI) and in patients with acute coronary syndromes (ACS) because this regimen has substantially decreased the rate of cardiovascular events. The variability in pharmacodynamic response as well as the.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.